|
|
Poll Results
Which insulins do you or your child use?
Vote for all that apply
Short acting insulins
NovoLog/Novorapid
27%
238
Humalog
22%
195
Regular/Actrapid/Velosulin
1%
14
Apidra
1%
2
Other short acting insulin
1%
1
Long acting insulins
Lantus
27%
244
Levemir
1%
4
NPH/Isophane/Insulatard
14%
127
Lente
1%
10
Ultralente
1%
7
Other long acting insulin
1%
10
Other
Premixed (70/30, etc.)
1%
13
Other insulin
1%
7
Don't use insulin
1%
2
Total votes: 930
Which insulins do you or your child use?
Poll dates: January 9 - 16, 2005
Total Votes: 874Insulin users today have a great variety of products from which to choose. In the past few years, two fast-acting analogs (NovoLog and Humalog) and one long-acting analog (Lantus) have been introduced and have changed the way many people use insulin. The use of Regular insulin among our readers has dropped off to just one percent. NPH use has dropped too, from 32% in 2000 to 14% in 2005.
This table shows readers' answers to this survey over the past four years:
Percentages based on use compared with all responses
Answer Jan 2005 Jan 2004 Jan 2003 Jan 2002 Mar 2000 Short acting insulins NovoLog 27% 26% 12% 3% -- Humalog 22% 26% 34% 37% 35% Regular 1% 2% 3% 4% 12% Apidra 1% -- -- -- -- Long acting insulins Lantus 27% 21% 17% 11% -- Levemir 1% -- -- -- -- NPH 14% 16% 22% 28% 32% Lente 1% 1% 1% 3% 4% Ultralente 1% 1% 2% 5% 7% Other Premixed 1% 1% 2% 2% 5% Other insulin 1% 1% 2% 2% 2% Looking at answers in the short-acting and long-acting insulins shows a dramatic change since 2000. The following graphs illustrate the rapid increase in use of insulin analogs and the concurrent decline in the use of Regular and NPH.
Rapid Acting Insulin Use
The rise in the use of NovoLog has been particularly significant since it was introduced in 2002. Among users of rapid-acting insulin, NovoLog is used by more than half of our visitors (53%), while use of Humalog continues to decline and is now at 43%. The use of Regular has declined to one percent of CWD visitors.
Data within rapid-acting insulin only
Data among all responsesLong Acting Insulin Use
Throughout 2004 and into 2005, the use of Lantus continued to increase among CWD visitors who report using long acting insulin. This year, almost two-thirds (62%) of people who use long acting insulin report using Lantus. The use of NPH dropped 20% in the past year and now stands at 32%. Few people use Lente and Ultralente. New this year is Levemir, but it is not yet available in the US.
Data within long-acting insulin only
Data among all responses[Download an Excel spreadsheet with the data and graphs from this poll]
|
|
|||
Last Updated: Wednesday March 16, 2005 15:38:01
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by Children With Diabetes, Inc, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, Privacy Policy, and Safe Harbor Policy.
© Children with Diabetes, Inc. 1995-2013. Comments and Feedback.